|
Monitoring the progress of Introgen's INGN 241 appears valuable because in 2002 data from preclinical studies indicated that INGN 241 acts by suppressing growth of a number of malignant tumors including melanoma and brain breast colon lung and prostate cancer. INGN 241 does not affect growth of normal cells. In addition it stimulated immune cells and acted as a radiosensitizer. INGN 241 in combination with chemotherapeutic products Adriamycin® Taxotere® Tamoxifen® and Herceptin® was shown to display supra- additive effects in inhibiting breast cancer growth and inducing cancer cell death.
The cross-link below is a press release related to findings presented at the 2003 annual meeting of the American Association of Cancer Research held earlier this month.
|
Threaded Mode